Historical record - last NADAC effective date: 8/22/2018
Product Information
CEFIXIME 100 MG/5 ML SUSP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $2.8771 per ML under NDC 68180040501. Its NADAC has been published 160 times since Oct 21, 2015.
FDA first approved this application on Feb 23, 2004.
Strength
100 mg/5mL
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180040501
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
8/22/2018
Active Ingredients
CEFIXIMEApproval Type
Generic (ANDA)
FDA Application
ANDA065129FDA Approved
2/23/2004
On Market Since
4/24/2015
Pharmacological Classes
Price Statistics
The NADAC for CEFIXIME 100 MG/5 ML SUSP has been published 160 times since Oct 21, 2015, and over the history we have for it it has declined 10.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8771 per ML |
|---|---|
| All-time high | $3.3767 (Dec 16, 2015) |
| All-time low | $2.6416 (Sep 20, 2017) |
| Median price | $3.0755 |
| Average price | $3.0572 |
| Largest weekly change | -16.1% (Sep 20, 2017) |
| Weeks tracked | 160 |
| Tracking since | Oct 21, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-10.3%
Last surveyed Aug 14, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CEFIXIME market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CEFIXIME market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFIXIME 100 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEFIXIME 100 MG/5 ML SUSP, manufactured by Lupin Pharmaceuticals Inc., is $2.8771 per ML (NDC 68180040501), effective Aug 14, 2019.
How has the price of CEFIXIME 100 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEFIXIME 100 MG/5 ML SUSP has declined 10.3%. It has been tracked across 160 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for CEFIXIME 100 MG/5 ML SUSP?
Since Oct 21, 2015, the NADAC for CEFIXIME 100 MG/5 ML SUSP has ranged from a low of $2.6416 (Sep 20, 2017) to a high of $3.3767 (Dec 16, 2015), with a median of $3.0755 per ML.
Are there cheaper alternatives to CEFIXIME 100 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of CEFIXIME 100 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CEFIXIME 100 MG/5 ML SUSP?
CEFIXIME 100 MG/5 ML SUSP (NDC 68180040501) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.